Brigatinib vs Ensartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Brigatinib
Marketed by Takeda Pharmaceutical Company
NCT02737501 · Phase 3 · completed
This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT04223596 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months (missed)
Result source: NCT03596866
Ensartinib · Ensacove
Marketed by Xcovery Holdings and partners
NCT02767804 · Phase 3 · active, not recruiting
This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)
Result source: NCT02767804
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Brigatinib | Ensartinib |
|---|---|---|
| PFS, median | 24.0 vs 11.1vs CrizotinibNCT0273750110 other results
| —Trial running · NCT06955325 |
| OS, median | 25.9bNCT020945738 other results
| —Trial running · NCT06955325 |
| ORR | 74.5% vs 62.3%vs CrizotinibNCT027375016 other results
| —Trial running · NCT06955325 |
| Duration of response, median | 33.1 vs 13.8vs CrizotinibNCT027375012 other results
| —Trial running · NCT06955325 |
PFS, median
- Brigatinib
- 24.0 vs 11.1vs CrizotinibNCT02737501
10 other results
- 19.3 vs 19.2 NCT03596866
- 16.8 vs 16.6 NCT03596866
- 9.2 NCT02094573
- 15.6 NCT02094573
- 12.6 NCT01449461
- 11 NCT01449461
- 5.4 NCT01449461
- 5.4 NCT01449461
- 5.4 NCT01449461
- 1.8 NCT01449461
- Ensartinib
- —Trial running · NCT06955325
OS, median
- Brigatinib
- 25.9bNCT02094573
8 other results
- 40.6 NCT02094573
- 21.3 NCT03535740
- 11.6 NCT01449461
- 17.9 NCT01449461
- 8.3 NCT01449461
- 7.3 NCT01449461
- 7.3 NCT01449461
- 5.3 NCT01449461
- Ensartinib
- —Trial running · NCT06955325
ORR
- Brigatinib
- 74.5% vs 62.3%vs CrizotinibNCT02737501
6 other results
- 45.5% NCT02094573
- 57.3% NCT02094573
- 26.2% NCT03535740
- 51.8% NCT02094573
- 56.4% NCT02094573
- 26.2% NCT03535740
- Ensartinib
- —Trial running · NCT06955325
Duration of response, median
- Brigatinib
- 33.1 vs 13.8vs CrizotinibNCT02737501
2 other results
- 12 NCT02094573
- 13.8 NCT02094573
- Ensartinib
- —Trial running · NCT06955325
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Brigatinib: 4 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Brigatinib | Ensartinib |
|---|---|---|
| Dropout rate | 85.4%90 mg QD/180 QDa NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results97.6% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone90 mg NCT02094573 · Phase 2 n/a: no completion milestone90 mg - 180 mg NCT02094573 · Phase 2 —90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence —240 mg NCT03535740 · Phase 2 · registry result, not featured evidence n/a: no completion milestone90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence n/a: no completion milestone90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence | 0%225 mgb NCT01625234 · Phase 1/2 show 7 more results0%225 mg NCT01625234 · Phase 1/2 0%250 mg NCT01625234 · Phase 1/2 0%200 mg NCT01625234 · Phase 1/2 0%100 mg NCT01625234 · Phase 1/2 0%50 mg NCT01625234 · Phase 1/2 0%25 mg NCT01625234 · Phase 1/2 n/a: no completion milestone200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —90 mg QD/180 QDa NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results— NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3.6%90 mg NCT02094573 · Phase 2 12.7%90 mg - 180 mg NCT02094573 · Phase 2 —90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence —240 mg NCT03535740 · Phase 2 · registry result, not featured evidence 3.8%90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence 16.7%90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 9.4%90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 26.7%240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 8.3%180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 11.1%120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 0%30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence | —225 mgb NCT01625234 · Phase 1/2 show 7 more results—225 mg NCT01625234 · Phase 1/2 —250 mg NCT01625234 · Phase 1/2 —200 mg NCT01625234 · Phase 1/2 —100 mg NCT01625234 · Phase 1/2 —50 mg NCT01625234 · Phase 1/2 —25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 41.2%90 mg QD/180 QDa NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results30.4% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 53.2%90 mg NCT02094573 · Phase 2 62.7%90 mg - 180 mg NCT02094573 · Phase 2 46.6%90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence 23.1%240 mg NCT03535740 · Phase 2 · registry result, not featured evidence 35.6%90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence 55.6%90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 43.8%90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 73.3%240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 62.5%180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 55.6%120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 16.7%30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence | 50%225 mgb NCT01625234 · Phase 1/2 show 7 more results43.6%225 mg NCT01625234 · Phase 1/2 50%250 mg NCT01625234 · Phase 1/2 54.5%200 mg NCT01625234 · Phase 1/2 40%100 mg NCT01625234 · Phase 1/2 33.3%50 mg NCT01625234 · Phase 1/2 25%25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 90 mg QD/180 QDa diarrhoea 57.4% blood creatine phosphokinase increased 50% cough 36% NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more resultsblood creatine phosphokinase increased 73.6% aspartate aminotransferase increased 56.8% alanine aminotransferase increased 47.2% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 90/180 mg diarrhoea 39.8% blood creatine phosphokinase increased 34% nausea 28.2% NCT03535740 · Phase 2 · registry result, not featured evidence 240 mg diarrhoea 53.8% blood creatine phosphokinase increased 38.5% aspartate aminotransferase increased 23.1% NCT03535740 · Phase 2 · registry result, not featured evidence 90 mg/180 mg blood creatine phosphokinase increased 77.9% hypertension 47.1% diarrhoea 45.2% NCT03410108 · Phase 2 · registry result, not featured evidence 90 mg QD fatigue 50% diarrhoea 44.4% headache 44.4% NCT01449461 · Phase 1/2 · registry result, not featured evidence 90 mg QD-180 mg QD diarrhoea 53.1% fatigue 50% nausea 50% NCT01449461 · Phase 1/2 · registry result, not featured evidence 240 mg QD/120 mg BID/300 mg QD fatigue 80% cough 53.3% diarrhoea 53.3% NCT01449461 · Phase 1/2 · registry result, not featured evidence 180 mg QD/90 mg BID nausea 68.8% diarrhoea 43.8% fatigue 39.6% NCT01449461 · Phase 1/2 · registry result, not featured evidence 120 mg QD/60 mg BID fatigue 50% nausea 50% aspartate aminotransferase increased 38.9% NCT01449461 · Phase 1/2 · registry result, not featured evidence 30 mg QD/60 mg QD abdominal pain 50% nausea 50% electrocardiogram qt prolonged 33.3% NCT01449461 · Phase 1/2 · registry result, not featured evidence | show 7 more results200 mg hypoalbuminaemia 100% anaemia 50% arthralgia 50% NCT02898116 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 11 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Brigatinib
show 2 more results
show 1 more result
show 1 more result
+ 20 further endpoints in the CSV export.
Ensartinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brigatinib's landscape · Ensartinib's landscape